Diversification accelerates while generic risks solidify
- Corcept's historical profit engine is Korlym for Cushing's syndrome.
- Lifyorli won FDA approval in March 2026 for platinum-resistant ovarian cancer and generated $47.6 million in its first quarter of availability.
- Management expects full-year 2026 revenue between $1.1 billion and $1.2 billion.
- The relacorilant Cushing's application faces a December 17, 2026 FDA target date.
- A July 2026 court ruling finalized the loss of Korlym patent protection against Teva.
Diversification is finally real
Corcept used to be almost entirely dependent on Korlym. That made the company simple to understand but fragile. In March 2026, the FDA approved Lifyorli for platinum-resistant ovarian cancer, and Corcept began selling it in April. That turns Corcept from a Cushing's syndrome company into a commercial business with two distinct franchises.
The Lifyorli launch is exceeding expectations. In its first full quarter, the drug generated $47.6 million in revenue, with more than 1,300 patients starting treatment and over 1,000 doctors prescribing it. This rapid adoption validates the company's expansion into oncology.
The bull case is that Lifyorli continues to ramp quickly, Korlym demand turns into steady cash flow as pharmacy bottlenecks clear, and the FDA approves relacorilant for Cushing's syndrome on its December 17, 2026 target date. A positive FDA decision would secure the company's next-generation endocrine franchise.
The bear case remains serious. Korlym faces certain generic pressure after Corcept exhausted its Teva patent appeals in July 2026. SG&A spending jumped to support the new launches. If Lifyorli sales momentum stalls or the FDA rejects relacorilant again, the company could struggle to offset the eventual decline of its core business.
Specialty drugs fund the pipeline
Corcept makes money by selling specialty medicines in the United States. Korlym and its authorized generic treat high blood sugar in adults with endogenous Cushing's syndrome. Lifyorli, which uses the same active drug as relacorilant, is sold with nab-paclitaxel for certain ovarian cancer patients.
The company relies on cash flow from the established Korlym franchise and the new Lifyorli launch to fund an R&D pipeline of selective cortisol modulators. Driven by strong early launch metrics and stabilized Korlym sales, management expects full-year 2026 revenue between $1.1 billion and $1.2 billion.
The model works best when specialty pharmacies, insurers, and doctors move patients through the system quickly. Corcept recently resolved prior authorization and pharmacy transition backlogs, clearing the way to capture strong underlying demand in the endocrine business.
Costs are rising with the bigger ambition. Selling, general, and administrative expenses increased significantly in 2026 to support commercialization of the hypercortisolism products and Lifyorli. That spending is sensible if both launches work, but painful if either one misses.
Korlym pays, Lifyorli grows
Korlym
Korlym treats hyperglycemia in adult patients with endogenous Cushing's syndrome. It remains the main revenue base, but it faces generic pressure.
Authorized generic Korlym
Corcept launched an authorized generic in June 2024. It helps defend volume, but it also lowers average selling price.
Lifyorli
Lifyorli was approved in March 2026 for certain platinum-resistant ovarian cancer patients and launched in April 2026. It generated $47.6 million in its first quarter.
Relacorilant for Cushing's syndrome
Corcept resubmitted the application in June 2026 after a previous rejection. The FDA set a target action date of December 17, 2026.
Miricorilant for MASH
Miricorilant is being studied for MASH, a liver disease linked to fat buildup and inflammation. Enrollment in the Phase 2b MONARCH trial is complete.
Dazucorilant for ALS
Dazucorilant is planned for a pivotal Phase 3 trial in ALS in 2026. This is a high-risk neurology program.
Nenocorilant in oncology
Nenocorilant is being tested with nivolumab in the Phase 1b SYNERGY trial for solid tumors. It is part of Corcept's broader bet on cortisol modulation in cancer.
One reported segment, two markets
Corcept operates as a single business segment. In Q2 2026, the company generated $208.6 million from endocrinology products and $47.6 million from the newly launched oncology product, Lifyorli.
What can break the story
Korlym generic erosion
High impact · High oddsCorcept lost its final Teva patent appeal in July 2026 when the court denied a rehearing. That finalizes the loss of patent protection and solidifies the long-term threat of revenue and margin erosion from generic entrants.
Slow Lifyorli ramp
High impact · Medium oddsLifyorli started strong with over 1,300 patients in Q2 2026. The next test is sustained revenue growth. If payer access, patient duration of therapy, or gross-to-net discounts disappoint, Lifyorli may not offset Korlym pressure.
Cushing's regulatory setback
High impact · Medium oddsThe FDA is reviewing the relacorilant resubmission for Cushing's syndrome with a December 17, 2026 target date. A second rejection would permanently impair the endocrine pipeline.
Launch spending outruns revenue
Medium impact · Medium oddsOperating expenses are rising to support the Lifyorli and hypercortisolism launches. If sales do not ramp fast enough to cover these costs, profits and cash flow could stay under pressure.
Legal overhang
Medium impact · Medium oddsCorcept faces an antitrust lawsuit from Teva scheduled for a March 2027 trial. The company is also dealing with a securities class action. These cases can cost money, take management time, and hurt investor trust.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Corcept Therapeutics Incorporated in Finn's Biotechnology industry ranking.
